• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee (PDF – 697KB)
 
Errata to the FDA Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee (PDF – 12KB)
 
 
Johnson & Johnson Pharmaceutical Research & Development, LLC
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
J&J Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee (PDF – 1.98MB)
 
Errata to the J&J Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee (PDF – 287KB)
 
 
Theravance, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Theravance Briefing Information for the November 17, 2011 Meeting of the Gastrointestinal Drugs Advisory Committee (PDF – 90KB)